We have covered biosimilars in this blog before. Biosimilars are biological products that are similar in potency, safety and efficacy to approved reference (or “innovator”) products, but are manufactured by…
One of the hottest areas of medicine is cancer immunotherapy. The importance of this field to medicine was highlighted last month with the announcement of the 2018 Nobel Prize winners…
Biologics are the fastest-growing class of therapeutic products in the United States. As products of genetic engineering technology, they were initially introduced in the 1980s and the segment has been…
Reported on 8 March by Eric Palmer from Fierce Pharma, 2018 marks a landmark event in the global biologics supply chain—for the first time, an FDA approved biologic will be…
We have reported before on the annual preview of mAb products published by the journal mAbs at the start of each new year. For 2018, Hélène Kaplon & Janice M.…
The eagerly awaited Part 2 of our review of bispecific antibodies (bsAbs) entitled “Therapeutic IgG-Like Bispecific Antibodies-Modular Versatility and Manufacturing” appears in the January 2018 issue of BioProcess International. In…
At Chamow & Associates we have an ongoing interest in therapeutic Fc-fusion proteins. We have published recently on the subject (A. Linderholm and S.M. Chamow, Immunoglobulin Fusion Proteins, Parts 1…
New this month, from Chamow & Associates’ Jennifer Bratt, Angela Linderholm, Bryan Monroe and Steven Chamow, is a review on bispecific antibodies (bsAbs) published in BioProcess International titled “Therapeutic IgG-like…
Until a few years ago, millions of American gout sufferers could buy colchicine, a long-established prescription drug to treat the painful ailment, for about $0.09 a pill. But in 2010,…
Monoclonal antibodies (mAbs) are remarkable proteins. Representing more than 50 FDA approved products for a variety medical indications, mAbs are the fastest growing class of new biologics today. Produced naturally…